Phase II study of high-dose ifosfamide in hepatocellular carcinoma.
A phase II study of high-dose ifosfamide in hepatocellular carcinoma was conducted among 17 Chinese patients. The dose of ifosfamide used was 2.5 g/m2 daily given as a continuous infusion for 5 days. In all, 15 patients were evaluable for tumour response. There was no complete or partial responder. The treatment was well tolerated. The most frequent toxicity was alopecia, which occurred in 11 patients, and 5 patients developed mild haematological toxicity. There was no evidence of liver or bladder toxicity. Overall, 14 patients were evaluable for survival. The median survival was 92 days (range, 30-568 days). We conclude that high-dose ifosfamide is well tolerated but ineffective in hepatocellular carcinoma in Chinese patients.
Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin.
J
J
Lin
W
W
Shiu
W T
WT
Leung
M
M
Tao
N
N
Leung
W Y
WY
Lau
A K
AK
Li
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D007069:Ifosfamide